SAVED
File name .JPG
File alt. text
Image should be px wide x px tall.
Select Image
home - Colon - Various Colitides - Diversion Colitis Written by Dr Sebastian Zeki

Diversion Colitis

Carbs SCFA’s (butyrate, acetate, propionate) Anaerobic bacterial metabolism Carbohydrates absorbed by ion exchange and diffusion and oxidised by colonocyte Normal Carbs SCFA’s (butyrate, acetate, propionate) Anaerobic bacterial metabolism Diverted colon Histological evidence of diversion colitis = 95%Symptomatic patients =10% Role of Carbohydrate in the Colon They supply 70% of the fuel used by mucosal cells.They modulate fluid and electrolyte transport.They regulate colonic motility.They regulate mucosal blood flow. Histological FeatureDistinction from IBD is difficult.Diffuse cellular infiltrate and prominent lymphoid follicular hyperplasia may suggest diversion colitis. Rectal bleeding, tenesmus, mucus discharge, and abdominal pain Begin within a few months after surgery or after a long delay. Treatments:Reanastomosis.Short chain fatty acid enemas.5 ASA. Diversion colitis Definition— Diversion colitis is an inflammatory process that occurs in segments of the colorectum that are diverted from the fecal stream by surgery. The enema solution consists of sodium acetate (60 mmol), sodium propionate (30 mmol) and sodium n-butyrate (40 mmol) with additional sodium chloride (22 mmol) to yield an osmolality of 280 to 290 mosmol/L which is similar to plasma. The pH is adjusted to 7.0 with sodium hydroxide. -bd for 6 weeks Written by Dr Sebastian Zeki

Related Stories

•Comparison of Three Minimally Invasive Surgical Approaches for Restorative Proctocolectomy in Ulcerative Colitis: A Retrospective Study

•Multi-omics Mendelian randomization and experimental validation identify PRKAB1 as a regulator of phosphatidylcholine metabolism in IBD

•The methanolic extract of Byrsonima intermedia mitigates colonic injury in experimental colitis through redox restoration, cytokine modulation, and tissue repair

•Cellular reprogramming and signaling control by kaempferol in colorectal cancer

•Selective COX-2 inhibitors for short-term musculoskeletal pain in inflammatory bowel disease in remission: a narrative review